Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sequential fulminant hepatitis and toxic epidermal necrolysis induced by tislelizumab: A case report.

Experimental and therapeutic medicine·2026
Same author

Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study.

Journal for immunotherapy of cancer·2026
Same author

B7-H3-mediated cis-inhibition of EGFR by a tumor-selective bispecific antibody enhances anti-tumor efficacy and minimizes toxicities.

Nature communications·2026
Same author

Draft whole-genome sequence of <i>Lachancea fermentati</i> JT139 isolated from Jamestown Island, Virginia.

Microbiology resource announcements·2026
Same author

Medicaid expansion is associated with improved survival in patients with resected Merkel cell carcinoma: A National Cancer Database analysis.

Journal of the American Academy of Dermatology·2025
Same author

Cytoplasmic calcium influx mediated by Lr14a regulates stomatal immunity against leaf rust in wheat.

Current biology : CB·2025

Related Experiment Video

Updated: Apr 18, 2026

Application of AlDeSense to Stratify Ovarian Cancer Cells Based on Aldehyde Dehydrogenase 1A1 Activity
09:59

Application of AlDeSense to Stratify Ovarian Cancer Cells Based on Aldehyde Dehydrogenase 1A1 Activity

Published on: March 31, 2023

1.5K

Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma.

Lili Yue1, Zhi-Ming Huang, Stephen Fong

  • 1Departments of aDermatology bSurgery, University California at San Francisco cDepartment of Dermatology, Veterans Affairs Medical Center, San Francisco dDepartment of Surgery, University California at Irvine, Irvine, California, USA.

Melanoma Research
|February 3, 2015
PubMed
Summary
This summary is machine-generated.

Aldehyde dehydrogenase 1 (ALDH1) inhibition targets tumorigenic melanoma cells. Combining ALDH1 inhibitors with chemotherapy reduced tumor growth and metastasis, suggesting a new therapeutic strategy for melanoma.

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.8K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

3.0K

Related Experiment Videos

Last Updated: Apr 18, 2026

Application of AlDeSense to Stratify Ovarian Cancer Cells Based on Aldehyde Dehydrogenase 1A1 Activity
09:59

Application of AlDeSense to Stratify Ovarian Cancer Cells Based on Aldehyde Dehydrogenase 1A1 Activity

Published on: March 31, 2023

1.5K
A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.8K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

3.0K

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Aldehyde dehydrogenase (ALDH+) cells are highly tumorigenic in melanoma.
  • ALDH represents a potential therapeutic target for melanoma treatment.
  • Understanding ALDH's role is crucial for developing effective therapies.

Purpose of the Study:

  • To investigate the therapeutic potential of ALDH1 inhibition in melanoma.
  • To evaluate the combined effects of ALDH1 inhibitors and chemotherapy.
  • To assess the impact of ALDH1A1 RNA silencing on melanoma growth and metastasis.

Main Methods:

  • Utilized chemical ALDH1 inhibitors (e.g., diethylaminobenzaldehyde) in combination with dacarbazine chemotherapy.
  • Employed shRNA to deplete ALDH1A1 in melanoma cells.
  • Assessed tumor growth, residual tumorigenic cells, and metastasis in mouse xenograft models.

Main Results:

  • Combined ALDH1 inhibition and dacarbazine chemotherapy reduced melanoma tumor growth and the number of residual tumorigenic cells.
  • ALDH1A1 depletion significantly delayed melanoma xenograft appearance and reduced tumor growth.
  • ALDH1A1 silencing markedly decreased melanoma metastasis and overall metastatic burden.

Conclusions:

  • ALDH1 inhibition shows promise as a therapeutic strategy for melanoma, potentially enhancing chemotherapy efficacy.
  • Targeting ALDH1 may reduce residual cancer cells, preventing tumor relapse.
  • ALDH1A1 depletion effectively inhibits melanoma growth and metastasis, indicating its critical role in disease progression.